Your shopping cart is currently empty

m7GTP sodium (7-Methyl-guanosine-5'-triphosphate sodium) is a structural analog of the mRNA cap that inhibits protein synthesis in vitro by binding to eIF4E (eukaryotic translation initiation factor), and is commonly used to study protein synthesis involving mRNA.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $149 | - | In Stock |
| Description | m7GTP sodium (7-Methyl-guanosine-5'-triphosphate sodium) is a structural analog of the mRNA cap that inhibits protein synthesis in vitro by binding to eIF4E (eukaryotic translation initiation factor), and is commonly used to study protein synthesis involving mRNA. |
| In vitro | m7GTP sodium acts as a competitive inhibitor of the eukaryotic translation initiation factor eIF4E. In various in vitro assays, m7GTP sodium is commonly used to block cap-dependent translation. For example, at 200 μM, m7GTP sodium effectively inhibits the binding of eIF4E to capped mRNAs in cell-free systems or lysates, impairing translation initiation[1]. |
| Synonyms | 7-Methyl-guanosine-5'-triphosphate sodium |
| Formula | C11H18N5O14P3.xNa |
| Smiles | CN1C=[N+](C2=C1C(=O)NC(=N2)N)C3C(C(C(O3)COP(=O)([O-])OP(=O)([O-])OP(=O)([O-])[O-])O)O.[Na+] xNa |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility Information | H2O: 200 mg/mL, Sonication is recommended. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.